CurrentRegence BlueCross BlueShieldPolicy 167

Intensity Modulated Radiotherapy (IMRT) for Tumors in Close Proximity to Organs at Risk

Customize your policy alerts

Sign up for regence Policy 167 alerts

Get alerted when Policy 167 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

This policy governs medical necessity and prior authorization for IMRT used to treat primary or metastatic tumors near organs at risk. Coverage depends on comparative 3D versus IMRT dose-volume analysis demonstrating that published organ dose constraints can be met only with IMRT.

Policy Summary

PayerRegence BlueCross BlueShield

PolicyIntensity Modulated Radiotherapy (IMRT) for Tumors in Close Proximity to Organs at Risk

Policy CodePolicy 167

Change TypeNo material change

Effective DateJanuary 1, 2026

Last ReviewDec 1, 2025

Next Review DateSeptember 1, 2026

Key ActionWith the preauthorization request, submit comparative 3D versus IMRT dose-volume histograms in color and the completed summary analysis demonstrating that only IMRT can meet the applicable published dose-volume constraints for organs at risk.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

2Treatment-plan approaches compared

6Required analysis-table elements

Only IMRTRequired conclusion

Not medically necessary

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentRegence BlueCross BlueShieldPolicy 167

Intensity Modulated Radiotherapy (IMRT) for Tumors in Close Proximity to Organs at Risk

Customize your policy alerts

Sign up for regence Policy 167 alerts

Get alerted when Policy 167 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerRegence BlueCross BlueShield

PolicyIntensity Modulated Radiotherapy (IMRT) for Tumors in Close Proximity to Organs at Risk

Policy CodePolicy 167

Change TypeNo material change

Effective DateJanuary 1, 2026

Last ReviewDec 1, 2025

Next Review DateSeptember 1, 2026

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

2Treatment-plan approaches compared

6Required analysis-table elements

Only IMRTRequired conclusion

Not medically necessary

When criteria are not met

3Example organs at risk

7Listed procedure codes

Medical Necessity Criteria

Covered IMRT for Tumors Near Organs at Risk

IMRT may be considered medically necessary for primary and metastatic tumors in close proximity to organs at risk when ALL of the following are met:

ALL of the following

The tumor is primary or metastatic and is in close proximity to one or more organs at risk.
Comparative three-dimensional (3D) versus IMRT dose/volume histograms are submitted in color.
A summary analysis, preferably presented in a table and submitted with the preauthorization request, demonstrates that only IMRT can meet the published dose/volume constraints for the organs at risk.
Quality assurance procedures are not required for preauthorization. A template for the comparative analysis table is available in the source policy.
The comparative analysis identifies the organ(s) at risk, dose constraint, source of the constraint, 3D dose, IMRT dose, and whether the constraint can be met only with IMRT.
Illustrative examples in the policy include: brachial plexus maximum < 66 Gy (RTOG), 3D 58 Gy versus IMRT 52 Gy—IMRT is not required because both meet the constraint; cauda equina maximum < 16 Gy (RTOG #0631), 3D 19 Gy versus IMRT 17 Gy—neither meets the constraint; and brainstem maximum < 54 Gy (QUANTEC), 3D 62 Gy versus IMRT 52 Gy—only IMRT meets the constraint.

Not Medically Necessary

IMRT is not medically necessary when the tumor does not meet the coverage criteria above.

ALL of the following

The tumor does not meet the stated criteria for medically necessary IMRT.

Medically Necessary IMRT

IMRT may be considered medically necessary when ALL of the following are met:

ALL of the following

IMRT reduces radiation to vital structures below recommended thresholds compared with an alternative radiation therapy technique.
The reduction applies to organs at risk, such as the heart, spinal cord, or esophagus, and is supported by the required comparative 3D versus IMRT dose/volume analysis.
The policy criteria for demonstrating that only IMRT can meet the applicable published dose/volume constraints are met.

Not Medically Necessary

IMRT is not medically necessary when the required comparative dose reduction is not demonstrated.

ANY of the following

IMRT does not reduce radiation to vital structures below recommended thresholds compared with an alternative radiation therapy technique.
The applicable policy criteria are not met.

Tumors that do not meet the policy criteria are excluded from medical necessity for IMRT under this policy.

IMRT is not medically necessary for tumors that do not meet the stated criteria. Specific indications addressed in Medicine policies 164, 165, or 166 should be evaluated under those policies, as applicable.

IMRT is also not medically necessary when it fails to reduce radiation to vital structures below recommended thresholds compared with alternative radiation therapy techniques; in that circumstance, improvement in net health outcomes has not been demonstrated.

Coding and Dose Documentation

Image fusion / treatment planningCPT

77399

Unlisted procedure, medical radiation physics, dosimetry and treatment devices, and special services

CPTCPT

77301	Intensity modulated radiotherapy plan, including dose volume histograms for target and critical structure partial tolerance specification.
77338	Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan.
77385	Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; simple (Deleted 01/01/2026).
77386	Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; complex (Deleted 01/01/2026).

HCPCSHCPCS

G6015	Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session (Deleted 01/01/2026).
G6016	Compensator-based beam modulation treatment delivery of inverse planned treatment using 3 or more high resolution (milled or cast) compensator, convergent beam modulated fields, per treatment session (Deleted 01/01/2026).

Radiation dose to vital structures

Required outcomeRadiation to vital structures must be below recommended thresholds.

ComparisonThe dose outcome is evaluated against alternative radiation therapy techniques.

Clinical purposeThe dose reduction supports reducing the risk of toxicity to organs at risk.

Authorization and Documentation Requirements

Prior Authorization

Submit Comparative Dosimetry With Preauthorization

Submit comparative 3D versus IMRT dose/volume histograms in color with the preauthorization request, along with the completed summary analysis demonstrating that only IMRT can meet published dose/volume constraints for organs at risk. Quality-assurance procedures for the submitted plans are not required for preauthorization.

Include the comparative histograms in color.
Submit the preferred completed summary analysis table before submission.

Documentation Required

Required Clinical and Imaging Documentation

Provide the clinical and imaging documentation needed to establish medical necessity and demonstrate that the policy criteria are met.

Clinical history.
Physical examination notes or chart notes.

Treatment Background

IMRT uses computer-optimized, variable-intensity radiation beams delivered through multiple shaped fields to conform radiation more closely to the tumor. This approach may reduce radiation exposure to surrounding normal tissues while respecting dose limits for nearby organs at risk.

Key Definitions

Organs at risk

DefinitionNormal tissues whose radiation sensitivity may significantly influence treatment planning or the prescribed radiation dose.

Treatment-planning roleThe sensitivity of these tissues helps determine treatment planning and the prescribed radiation dose.

Clinical vulnerabilityOrgans at risk may be particularly vulnerable to clinically important complications from radiation toxicity.

Intensity-modulated radiotherapy (IMRT)

TechniqueA radiation treatment technique that modulates the intensity of overlapping radiation beams projected on the target and uses multiple-shaped treatment fields.

Planning softwareComputer software optimizes the location, shape, and intensity of treatment beam ports.

Policy Summary

PayerRegence BlueCross BlueShield

PolicyIntensity Modulated Radiotherapy (IMRT) for Tumors in Close Proximity to Organs at Risk

Policy CodePolicy 167

Change TypeNo material change

Effective DateJanuary 1, 2026

Last ReviewDec 1, 2025

Next Review DateSeptember 1, 2026

SourceLink

On This Page

Relevant imaging reports documenting tumor proximity to an organ at risk and the applicable medical-necessity criteria.

Documentation Required

Demonstrate Comparative IMRT Necessity

The comparative submission must demonstrate that the dose constraints cannot be met through 3D planning but can be met with IMRT. Include comparative 3D versus IMRT dose/volume histograms in color and the completed analysis with the preauthorization request.

Document the tumor’s close proximity to one or more organs at risk.
Show the comparative 3D and IMRT dose/volume results.
State whether the dose constraint can be met only with IMRT.

Documentation Required

Complete Every Analysis-Table Field

Complete the summary analysis table for every relevant organ at risk. The analysis must contain all required fields and explicitly answer whether the dose constraint can be met only with IMRT.

Organ at risk.
Dose constraint employed.
Source of the dose constraint.
Dose achieved through 3D planning.
Dose achieved through IMRT.
Yes-or-no answer to: “Can the dose constraint only be met with IMRT?”

Documentation Required

Document Organ-at-Risk Benefit

Document the tumor’s proximity to an organ at risk and show that IMRT reduces radiation to that vital structure below the applicable recommended threshold compared with the alternative radiation technique. This documentation supports medical necessity when the policy criteria are met.

Identify the organ at risk involved, such as the heart, spinal cord, or esophagus.
Provide the applicable published or otherwise supported dose constraint and its source.
Compare the dose achieved with 3D planning against the dose achieved with IMRT.
Demonstrate that the reduction is clinically meaningful and meets the recommended threshold only with IMRT.

Denial Risk

Tumor Does Not Meet IMRT Necessity Criteria

IMRT is not medically necessary when the tumor does not meet the policy criteria for close proximity to an organ at risk and comparative dosimetry demonstrating IMRT necessity.

Denial risk applies when the required proximity, comparative histogram, or dose-constraint criteria are not met.
Use the applicable cross-referenced policies for specific indications addressed under Policies 164, 165, or 166.

Denial Risk

Insufficient Comparative Dosimetry Risks Adverse Review

Missing or incomplete comparative dosimetry may adversely affect the authorization review and decision. Submit color 3D-versus-IMRT dose/volume histograms and the completed summary analysis with the preauthorization request.

Do not omit the comparative histograms.
Complete the preferred summary analysis table before submission.
Quality assurance for the submitted 3D and IMRT plans is not required with a preauthorization request.

Denial Risk

Failure to Demonstrate Required Dose Reduction

IMRT may be considered medically necessary only when it reduces radiation to an organ at risk below the recommended threshold compared with the alternative technique and the policy criteria are otherwise met. If IMRT does not produce the required dose reduction, the treatment is considered not medically necessary.

Show the applicable recommended threshold and its source.
Compare the 3D and IMRT doses for each relevant organ at risk.
Document that the threshold is achieved with IMRT and not through 3D planning when the policy requires IMRT.

Imaging inputsPlanning uses computed tomography (CT) images and magnetic resonance imaging (MRI).

Beam-shaping deviceA multileaf collimator (MLC) is used with a computer algorithm to support inverse treatment planning.

Inverse-planning parametersThe plan incorporates the prescribed target dose, acceptable dose heterogeneity, adjacent normal tissues to avoid, and dose limits for adjoining organs at risk.

Three-dimensional conformal radiation therapy (3D-CRT)

Imaging approachTreatment planning uses three-dimensional images, usually from computed tomography (CT) scans.

Anatomic delineationImaging delineates tumor boundaries and distinguishes tumor tissue from adjacent normal tissue and nearby organs at risk for radiation damage.

Dose calculationComputer algorithms estimate cumulative radiation dose delivered to each volume of interest by summing the contribution from each shaped beam.

Treatment deliveryPatient positioning, reproducible radiation portals, and immobilization help maintain consistent beam axes across treatment sessions.